Unprecedented Insights
ImaginAb is an emerging immune-oncology imaging company developing a pipeline of novel products that give physicians unprecedented insights into the patient’s health—enabling better patient selection and treatment monitoring for immuno-oncology therapies and other drugs.
Harnessing the specificity of monoclonal antibodies, ImaginAb designs and engineers small, highly targeted proteins known as minibodies that image important molecular targets using standard Positron Emission Tomography (PET).
Our imaging tools help physicians answer important clinical questions, improving the path of care and ultimately helping patients live longer, healthier lives.
ACCURACY
INNOVATION
CLARITY
BETTER DATA
ImaginAb and NEUVOGEN Announce Licensing Agreement for CD8 ImmunoPET Technology
ImaginAb Inc, a leading global provider of immuno-oncology imaging agents and NEUVOGEN, an immuno-oncology company developing next generation therapeutic whole cell cancer vaccines, announced they have signed a multi-year non-exclusive licensing agreement.
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
ImaginAb Inc., a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc.
Clarity Pharmaceuticals and ImaginAb to collaborate on new cancer targets
Clarity Pharmaceuticals and ImaginAb to collaborate on new cancer targets.